Cross-Sector entity
All 1 tracked stories fall under one category: gene-therapy. CRISPR-Cas9 is most often covered alongside Asian Elephant, which appears in 1 of these 1 story. CRISPR-Cas9 appears in 1 tracked Cross-Sector story from March 4, 2026. The tracked stories average 4 original sources each.
1 verified story tracked
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: gene-therapy. CRISPR-Cas9 is most often covered alongside Asian Elephant, which appears in 1 of these 1 story. CRISPR-Cas9 appears in 1 tracked Cross-Sector story from March 4, 2026. The tracked stories average 4 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CRISPR-Cas9. Shared-story counts are live from our verified record — not editorial picks.
Target Birth Date
Projected window for the birth of the first mammoth-elephant hybrid calf.
Dubai Biovault
Colossal announces the opening of a major genetic preservation facility in Dubai.
Series B Funding
Total funding surpasses $225M, valuing the company at over $1 billion.
Dodo Project Announced
The company expands its portfolio to include the de-extinction of the dodo bird.
Company Launch
Colossal Biosciences officially launches with $15M in seed funding to revive the woolly mammoth.
Colossal Biosciences is advancing its ambitious plan to 'de-extinct' the woolly mammoth using CRISPR technology, sparking intense debate over ecological ethics and resource allocation. While the company frames the project as a climate solution, critics argue it distracts from urgent conservation efforts for existing endangered species.
Source: iowapublicradio.org · wdiy.org
